They suggest that rAAV-mediated, muscle-specific expression of TNALP-D10 through intramuscular administration of therapeutic rAAV-8 may be a promising alternative to ERT to treat severe infantile forms of HPP. The gene discussed is ALPL; the disease is hypophosphatasia.